PH with COPD: Is Sildenafil an Effective Treatment Option?

2020-12-21T15:28:11-05:00October 26th, 2018|

by Phyllis Hanlon, Contributing Writer All of the 14 targeted therapies for pulmonary hypertension (PH) are approved for use in patients with World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH), with one therapy also approved for use in patients with inoperable or recurrent WHO Group 4 PH (chronic thromboembolic pulmonary hypertension,

PHA Recognizes Respiratory Care Week

2020-12-21T15:28:12-05:00October 19th, 2018|

In recognition of Respiratory Care Week Oct. 21-27, the Pulmonary Hypertension Association (PHA) interviewed a registered respiratory therapist and certified pulmonary function technician. Tonya Zeiger, R.R.T., CPFT, is the pulmonary hypertension (PH) coordinator and associate in pulmonary medicine at the Mayo Clinic’s Jacksonville, Fla. campus, a PHA-accredited Center of Comprehensive Care (CCC). In this interview,

Using a Risk Score Calculator to Predict Survival Rates

2020-12-21T15:28:18-05:00October 12th, 2018|

by Phyllis Hanlon, Contributing Writer The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL registry) is a study of approximately 3,500 people with World Health Organization (WHO) Group 1 pulmonary hypertension (pulmonary arterial hypertension, or PAH) in the U.S. Study participants who were followed 2006-2011 contributed important information to the pulmonary hypertension (PH)

PHA on the Road – Long Beach Welcomes More Than 200 PH Community Members

2020-12-21T15:28:20-05:00October 5th, 2018|

The Pulmonary Hypertension Association (PHA) hosted a PHA on the Road: PH Patients and Families Education Forum Saturday, Sept. 29, in Long Beach, Calif. The forum brought together people with pulmonary hypertension (PH), their caregivers, families and friends, and PH-treating health care professionals for a day of learning and networking. The forum’s opening session

Availability of Implantable System for Remodulin Likely Late 2019

2020-12-21T15:27:13-05:00September 14th, 2018|

The Food and Drug Administration (FDA) recently approved the Implantable System for Remodulin® (ISR), a collaboration between United Therapeutics Corporation and Medtronic. The ISR is approved for adults with functional class I, II and III pulmonary arterial hypertension (PAH) who are receiving intravenous (IV) treprostinil therapy. There are a very limited number of ISRs currently

Navigating Access to Generic Therapy

2020-12-21T15:27:15-05:00September 14th, 2018|

The Pulmonary Hypertension Association (PHA) reported Aug. 17 that generic tadalafil was approved by the Food and Drug Administration (FDA) and suggested that pulmonary hypertension (PH) patients taking Adcirca® discuss the implications with their care teams. Since then, generic tadalafil has become available through many health insurance plans. In addition, PHA has been advised

Treating PH: Joint Symposium Discusses Options

2020-12-21T15:27:16-05:00September 7th, 2018|

by Phyllis Hanlon, Contributing Writer Although there are 14 different Food and Drug Administration (FDA)-approved therapies for treating World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH), there remains a need for treatments that can be used across varying classifications of PH. In 2017, the Critical Care Medicine Department of

Share Your Oxygen Experiences: PHA Responds to Proposed Changes to Medicare Oxygen Coverage

2020-12-21T15:27:17-05:00September 7th, 2018|

The Centers for Medicare and Medicaid Services (CMS) has proposed significant changes to how home oxygen (also known as supplemental oxygen) is regulated and paid for. The Pulmonary Hypertension Association (PHA) is taking action to improve the pulmonary hypertension (PH) community’s experience accessing home oxygen. If you have been prescribed home oxygen, you can help

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2020-12-21T15:25:56-05:00August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

FDA Approves Generic Version of Adcirca®; Additional Approvals May Come Soon

2020-12-21T15:26:03-05:00August 17th, 2018|

The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.